Could a blood injection treat erectile dysfunction? new trial investigates

NCT ID NCT06768177

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study compares platelet-rich plasma (PRP) injections to the standard drug alprostadil (Caverject) for treating moderate to severe erectile dysfunction. Sixty men will receive both treatments in a crossover design, with each treatment given as six weekly injections. The main goal is to see if PRP improves erectile function scores more than alprostadil after 24 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Platelet-rich plasma (PRP) injection
What this could lead to
If PRP works, it could offer a new, natural treatment option for erectile dysfunction without relying on standard drugs.
What could go wrong
This is a small, early-stage crossover trial with only 60 participants. PRP is not yet proven for ED, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ERECTILE DYSFUNCTION ASSOCIATED WITH TYPE 2 DIABETES MELLITUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Policlinico di Bari - Azienda Ospedaliero Universitaria Consorziale Policlinico

    Bari, 70124, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.